Place Raymond Blyckaerts, 13
B-1050 Brussels, Belgium

Opening hours:
Mon to Thu: 10h - 12h30 and 13h30 - 17h
Fri: 10h - 12h30 and 13h30 - 16h


+3226269640
Google maps


Find us on
Google Maps
To subscribe to our newsletter, please click here. If you would like to become an EATG member, please fill in the form here. You can also subscribe to our RSS feed by clicking here.
You can also follow us on one of these media :
TAGS

27/08/2015
HIV particles do not cause AIDS, our own immune cells do

The virus turns host immune cells into suicide machines, using them to spread the virus and cause the progression from HIV to AIDS SAN FRANCISCO, CA—Researchers from the Gladstone Institutes have revealed that HIV does not cause AIDS by the virus’s direct effect on the host’s immune cells, but rather through the...

Read more...





27/08/2015
MSM with HIV show greater rate of abnormal anal cytology

Data published in The Journal of Infectious Diseases demonstrated that HIV-positive men who have sex with men, and those with persistent high-risk HPV, had a higher incidence of abnormal anal cytology. “Our analysis of longitudinal data from this large prospective cohort study of HIV-infected MSM, women, and [men who have sex with women (MSW)] has demonstrated a high...

Read more...

Source Source: Healio





27/08/2015
One in four hepatitis C patients denied initial approval for drug treatment

Nearly one in four patients with chronic hepatitis C (HCV) are denied initial approval for a drug therapy that treats the most common strain of the infection, according to a Yale School of Medicine study. The finding, published Aug. 27 in PLOS ONE , identifies a new barrier to caring for patients with this severe condition. Prior to the FDA approval of novel antiviral therapies...

Read more...

Source Source: Yale University





27/08/2015
FDA: Edurant (rilpivirine) labeling updated

On August 26, 2015 the Edurant (rilpivirine) product labeling was updated to include the use of rilpivirine in combination with other antiretroviral agents for the treatment of HIV-1 infection to include treatment-naïve pediatric patients from 12 to less than 18 years of age with HIV-1 RNA less than or equal to 100,00 copies/mL. The summary of the changes are provided here .

Read more...

Source Source: FDA

Tags: Treatment, FDA




27/08/2015
Gilead applies for PrEP approval in Canada

Gilead Sciences has applied for approval of Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP) in Canada, HomoCulture.com reports. If the country’s health ministry, Health Canada, approves the new indication for the antiretroviral (ARV), Canada would follow the United States to become only the second nation in the world to give the green light to this new...

Read more...

Source Source: POZ